UT MD Anderson Cancer Center
Department of Gynecologic Oncology & Reproductive Medicine
Dr. Anil K. Sood is Professor in the Department of Gynecologic Oncology & Reproductive Medicine at the UT MD Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program and co-leads the Ovarian Cancer Moonshot Program. Dr. Sood received his medical degree from the University of North Carolina, Chapel Hill. A major and consistent theme of his scientific research has been on understanding human cancer biology and converting lab discoveries into novel therapeutics. His research group has made several seminal research contributions in the fields of tumor microenvironment, nanomedicine, and neuroendocrine effects on cancer biology. Dr. Sood has received recognition for his research accomplishments including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. He is an elected member of the American Society for Clinical Investigation (ASCI), the American Association for the Advancement of Science (AAAS), the Association of American Physicians (AAP), and the National Academy of Medicine (NAM). Dr. Sood was selected as an American Cancer Society Research Professor in 2017.
Moderator of 2 Sessions
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Chair(s)
Session Icon
Session Description
This session is dedicated to innovations in ovarian cancer biology, surgery and treatment. Speakers in this session will cover the role of “biology” in clinical outcomes and potential for surgical decision making, timing and new approaches. With the growing interest in intraoperative treatments, a critical appraisal of HIPEC will be performed. The second part will discuss current and emerging systemic therapies in the first-line setting and how the ongoing trials may change clinical practice. Next, several “hot topics” in ovarian cancer will be presented, including the mechanisms of resistance to PARP inhibitors, front-line maintenance therapy as part of standard-of-care (SOC) for at least 50% of women with ovarian cancer and the new and very promising developmental therapies. To close this session dedicated to ovarian cancer, a debate on the role of surgery for relapsed disease from the US and European perspectives will be debated.
Session Type
Plenary Session
Date
10/01/2022
Session Time
09:15 AM - 10:00 AM
Room
Hall 405
Session Icon
Session Description
Four oral abstract presentations with various global speakers. Focused plenary presenters were also requested to submit E-Posters which you can find in the E-Poster Gallery on the Virtual Platform and IGCS 2022 Mobile App.
Presenter of 2 Presentations
PANEL 3: Current level of evidence supporting HIPEC in clinical care (30 min) – moderated by Anil Sood
Session Name
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Session Icon
Presenter
Lecture Time
05:18 PM - 05:18 PM
• DEBATE 1: Pro
Session Name
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Session Icon
Presenter
Lecture Time
04:02 PM - 04:16 PM